Sep. 29, 2009 (Business Wire) -- Seattle Genetics, Inc. (Nasdaq: SGEN) announced today that company management will present at the Fourth Annual JMP Securities Healthcare Focus Conference on Monday, October 5, 2009, at 8:30 a.m. Eastern Time. The conference is being held at The New York Palace Hotel in New York City.
A webcast of the presentation will be available live and for replay from the Seattle Genetics website, www.seattlegenetics.com, under the “investors & news” section.
About Seattle Genetics
Seattle Genetics is a clinical stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer and autoimmune disease. The company’s lead product candidate, brentuximab vedotin (SGN-35), is in a pivotal trial under a special protocol assessment with the FDA. Brentuximab vedotin is empowered by Seattle Genetics’ proprietary ADC technology comprising highly potent synthetic drugs and stable linkers for attaching the drugs to monoclonal antibodies. In addition, Seattle Genetics has two other product candidates in ongoing late-stage clinical trials: lintuzumab (SGN-33) and dacetuzumab (SGN-40) and one in early-stage clinical trials, SGN-70. Dacetuzumab is being developed under a worldwide collaboration with Genentech (a wholly owned member of the Roche Group). Seattle Genetics has collaborations for its ADC technology with a number of leading biotechnology and pharmaceutical companies, including Genentech, Bayer, CuraGen, Progenics, Daiichi Sankyo, MedImmune, a subsidiary of AstraZeneca, and Millennium: The Takeda Oncology Company, as well as an ADC co-development agreement with Agensys, a subsidiary of Astellas Pharma. More information can be found at www.seattlegenetics.com.
